Shenzhen New Industries Biomedical Engineering Co., Ltd.
300832
Rank in Stocks
#2881
Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the... Shenzhen New Industries Biomedical Engineering Co., Ltd., engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals in China and internationally. It offers immunoassay machine, biochemistry/electrolyte, integrated system, lab automation, molecular diagnostics, hemolumi and rapid test solutions. The company was founded in 1995 and is based in Shenzhen, China.
Share Price
$8.03
Market Cap
$6.31B
Change (1 day)
1.07%
Change (1 year)
-8.04%
Country
CN
Trade Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832)
Category
Healthcare
Revenue for Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832)
Revenue in Jun 2026 TTM: $720.60M
According to Shenzhen New Industries Biomedical Engineering Co., Ltd. latest financial reports the company's current revenue (TTM) is $720.60M. In 2024 the company made a revenue of $621.36M an increase over the revenue in the year 2023 that was $555.15M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Shenzhen New Industries Biomedical Engineering Co., Ltd. from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $720.60M | 10.16% |
| 2025 | $654.16M | 5.28% |
| 2024 | $621.36M | 11.93% |
| 2023 | $555.15M | 25.68% |
| 2022 | $441.72M | 10.30% |
| 2021 | $400.48M | 19.19% |
| 2020 | $336.00M | 39.13% |
| 2019 | $241.49M | 20.06% |
| 2018 | $201.15M | 14.74% |
| 2017 | $175.30M | 31.94% |
| 2016 | $132.87M | 17.92% |
| 2015 | $112.67M | 27.99% |
| 2014 | $88.03M | 41.22% |
| 2013 | $62.34M | 50.62% |
| 2012 | $41.39M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $48.23B | 6,592.92% |
US
|
|
| $37.54B | 5,109.85% |
IE
|
|
| $25.84B | 3,485.50% |
US
|
|
| $21.00B | 2,813.69% |
US
|
|
| - | - |
DE
|
